Ischaemia-free liver transplantation in humans: a first-in-human trial
Summary: Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences.Methods Ischaemia-free liver tra...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0d55f75fdf2c4f79ae6d5716985bf8c4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0d55f75fdf2c4f79ae6d5716985bf8c4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0d55f75fdf2c4f79ae6d5716985bf8c42021-12-02T05:04:02ZIschaemia-free liver transplantation in humans: a first-in-human trial2666-606510.1016/j.lanwpc.2021.100260https://doaj.org/article/0d55f75fdf2c4f79ae6d5716985bf8c42021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666606521001693https://doaj.org/toc/2666-6065Summary: Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences.Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT).Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach.Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers.Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology.Panel: Research in contextZhiyong Guo, M.D., Ph.D.Qiang Zhao, M.D., Ph.D.Shanzhou Huang, M.D., Ph.D.Changjun Huang, M.D.Dongping Wang, M.D., Ph.D.Lu Yang, M.D., Ph.D.Jian Zhang, M.Sc.Maogen Chen, M.D., Ph.D.Linwei Wu, M.D., Ph.D.Zhiheng Zhang, M.D.Zebin Zhu, M.D., Ph.D.Linhe Wang, M.D.Caihui Zhu, M.D.Yixi Zhang, M.D., Ph.D.Yunhua Tang, M.D., Ph.D.Chengjun Sun, M.D.Wei Xiong, M.D.Yuekun Shen, M.D., Ph.D.Xiaoxiang Chen, M.D.Jinghong Xu, M.D.Tielong Wang, M.D.Yi Ma, M.D., Ph.D.Anbin Hu, M.D., Ph.D.Yinghua Chen, M.D., Ph.D.Xiaofeng Zhu, M.D., Ph.D.Jian Rong, M.D., Ph.D.Changjie Cai, M.D., Ph.D.Fengqiu Gong, M.P.H.Xiangdong Guan, M.D., Ph.D.Wenqi Huang, M.D., Ph.D.Dicken Shiu-Chung Ko, M.D., Ph.D.Xianchang Li, M.D., Ph.D.Stefan G Tullius, M.D., Ph.D.Jiefu Huang, M.D., Ph.D.Weiqiang Ju, M.D., Ph.D.Xiaoshun He, M.D., Ph.D.ElsevierarticlePublic aspects of medicineRA1-1270ENThe Lancet Regional Health. Western Pacific, Vol 16, Iss , Pp 100260- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Public aspects of medicine RA1-1270 |
| spellingShingle |
Public aspects of medicine RA1-1270 Zhiyong Guo, M.D., Ph.D. Qiang Zhao, M.D., Ph.D. Shanzhou Huang, M.D., Ph.D. Changjun Huang, M.D. Dongping Wang, M.D., Ph.D. Lu Yang, M.D., Ph.D. Jian Zhang, M.Sc. Maogen Chen, M.D., Ph.D. Linwei Wu, M.D., Ph.D. Zhiheng Zhang, M.D. Zebin Zhu, M.D., Ph.D. Linhe Wang, M.D. Caihui Zhu, M.D. Yixi Zhang, M.D., Ph.D. Yunhua Tang, M.D., Ph.D. Chengjun Sun, M.D. Wei Xiong, M.D. Yuekun Shen, M.D., Ph.D. Xiaoxiang Chen, M.D. Jinghong Xu, M.D. Tielong Wang, M.D. Yi Ma, M.D., Ph.D. Anbin Hu, M.D., Ph.D. Yinghua Chen, M.D., Ph.D. Xiaofeng Zhu, M.D., Ph.D. Jian Rong, M.D., Ph.D. Changjie Cai, M.D., Ph.D. Fengqiu Gong, M.P.H. Xiangdong Guan, M.D., Ph.D. Wenqi Huang, M.D., Ph.D. Dicken Shiu-Chung Ko, M.D., Ph.D. Xianchang Li, M.D., Ph.D. Stefan G Tullius, M.D., Ph.D. Jiefu Huang, M.D., Ph.D. Weiqiang Ju, M.D., Ph.D. Xiaoshun He, M.D., Ph.D. Ischaemia-free liver transplantation in humans: a first-in-human trial |
| description |
Summary: Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences.Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT).Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach.Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers.Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology.Panel: Research in context |
| format |
article |
| author |
Zhiyong Guo, M.D., Ph.D. Qiang Zhao, M.D., Ph.D. Shanzhou Huang, M.D., Ph.D. Changjun Huang, M.D. Dongping Wang, M.D., Ph.D. Lu Yang, M.D., Ph.D. Jian Zhang, M.Sc. Maogen Chen, M.D., Ph.D. Linwei Wu, M.D., Ph.D. Zhiheng Zhang, M.D. Zebin Zhu, M.D., Ph.D. Linhe Wang, M.D. Caihui Zhu, M.D. Yixi Zhang, M.D., Ph.D. Yunhua Tang, M.D., Ph.D. Chengjun Sun, M.D. Wei Xiong, M.D. Yuekun Shen, M.D., Ph.D. Xiaoxiang Chen, M.D. Jinghong Xu, M.D. Tielong Wang, M.D. Yi Ma, M.D., Ph.D. Anbin Hu, M.D., Ph.D. Yinghua Chen, M.D., Ph.D. Xiaofeng Zhu, M.D., Ph.D. Jian Rong, M.D., Ph.D. Changjie Cai, M.D., Ph.D. Fengqiu Gong, M.P.H. Xiangdong Guan, M.D., Ph.D. Wenqi Huang, M.D., Ph.D. Dicken Shiu-Chung Ko, M.D., Ph.D. Xianchang Li, M.D., Ph.D. Stefan G Tullius, M.D., Ph.D. Jiefu Huang, M.D., Ph.D. Weiqiang Ju, M.D., Ph.D. Xiaoshun He, M.D., Ph.D. |
| author_facet |
Zhiyong Guo, M.D., Ph.D. Qiang Zhao, M.D., Ph.D. Shanzhou Huang, M.D., Ph.D. Changjun Huang, M.D. Dongping Wang, M.D., Ph.D. Lu Yang, M.D., Ph.D. Jian Zhang, M.Sc. Maogen Chen, M.D., Ph.D. Linwei Wu, M.D., Ph.D. Zhiheng Zhang, M.D. Zebin Zhu, M.D., Ph.D. Linhe Wang, M.D. Caihui Zhu, M.D. Yixi Zhang, M.D., Ph.D. Yunhua Tang, M.D., Ph.D. Chengjun Sun, M.D. Wei Xiong, M.D. Yuekun Shen, M.D., Ph.D. Xiaoxiang Chen, M.D. Jinghong Xu, M.D. Tielong Wang, M.D. Yi Ma, M.D., Ph.D. Anbin Hu, M.D., Ph.D. Yinghua Chen, M.D., Ph.D. Xiaofeng Zhu, M.D., Ph.D. Jian Rong, M.D., Ph.D. Changjie Cai, M.D., Ph.D. Fengqiu Gong, M.P.H. Xiangdong Guan, M.D., Ph.D. Wenqi Huang, M.D., Ph.D. Dicken Shiu-Chung Ko, M.D., Ph.D. Xianchang Li, M.D., Ph.D. Stefan G Tullius, M.D., Ph.D. Jiefu Huang, M.D., Ph.D. Weiqiang Ju, M.D., Ph.D. Xiaoshun He, M.D., Ph.D. |
| author_sort |
Zhiyong Guo, M.D., Ph.D. |
| title |
Ischaemia-free liver transplantation in humans: a first-in-human trial |
| title_short |
Ischaemia-free liver transplantation in humans: a first-in-human trial |
| title_full |
Ischaemia-free liver transplantation in humans: a first-in-human trial |
| title_fullStr |
Ischaemia-free liver transplantation in humans: a first-in-human trial |
| title_full_unstemmed |
Ischaemia-free liver transplantation in humans: a first-in-human trial |
| title_sort |
ischaemia-free liver transplantation in humans: a first-in-human trial |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/0d55f75fdf2c4f79ae6d5716985bf8c4 |
| work_keys_str_mv |
AT zhiyongguomdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT qiangzhaomdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT shanzhouhuangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT changjunhuangmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT dongpingwangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT luyangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT jianzhangmsc ischaemiafreelivertransplantationinhumansafirstinhumantrial AT maogenchenmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT linweiwumdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhihengzhangmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zebinzhumdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT linhewangmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT caihuizhumd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yixizhangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yunhuatangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT chengjunsunmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT weixiongmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yuekunshenmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xiaoxiangchenmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT jinghongxumd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT tielongwangmd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yimamdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT anbinhumdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yinghuachenmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xiaofengzhumdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT jianrongmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT changjiecaimdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT fengqiugongmph ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xiangdongguanmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT wenqihuangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT dickenshiuchungkomdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xianchanglimdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT stefangtulliusmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT jiefuhuangmdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT weiqiangjumdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xiaoshunhemdphd ischaemiafreelivertransplantationinhumansafirstinhumantrial |
| _version_ |
1718400632606425088 |